Clinical Trial Update: A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical study of MEDI-551 in adults with relapsed or refractory advanced B-cell malignancies completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies
• Cancer

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: B-cell Malignancies, Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-13